Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 4/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102901 | 1.00 | SLC5A1 (0.48) | SLC5A1SLC5A2TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10102863 | 1.00 | SLC5A1 (0.48) | SLC5A1SLC5A2TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15198140 | 0.90 | ALDH1A1 (0.49) | SLC5A1SLC5A2TDP1ALDH1A1TYR | |
| SCHEMBL15198316 | 0.90 | ALDH1A1 (0.49) | SLC5A1SLC5A2TDP1ALDH1A1TYR | |
| SCHEMBL10119569 | 0.90 | ALDH1A1 (0.49) | SLC5A1SLC5A2TDP1ALDH1A1TYR | |
| SCHEMBL10108864 | 0.90 | ALDH1A1 (0.49) | SLC5A1SLC5A2TDP1ALDH1A1TYR | |
| SCHEMBL10103011 | 0.85 | TYR (0.48) | SLC5A1SLC5A2TDP1TYR | |
| SCHEMBL10103041 | 0.85 | TYR (0.48) | SLC5A1SLC5A2TDP1TYR | |
| SCHEMBL10102861 | 0.85 | SLC5A1 (0.43) | SLC5A1SLC5A2TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10102899 | 0.85 | SLC5A1 (0.43) | SLC5A1SLC5A2TDP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012012339-A2 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG ANALOGS | NuTek Pharma Ltd. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | UGT1A3, GCG, UGT1A1 | SLC5A1 62/4885SLC5A2 79/4885TDP1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.